Biopharmaceutical

Enterome to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

Tuesday, September 22, 2020 - 8:00am

Enterome has two unique platforms that are generating highly promising drug candidates:

Key Points: 
  • Enterome has two unique platforms that are generating highly promising drug candidates:
    OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463).
  • EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.
  • EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
  • Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed byleading venture capital investors.

Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Monday, September 21, 2020 - 11:09pm

The company is presenting at 9:10 AM ET on September 22nd.

Key Points: 
  • The company is presenting at 9:10 AM ET on September 22nd.
  • For those interested in participating in the conference, please email opcoconferences@opco.com to obtain the link.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com.

Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit

Monday, September 21, 2020 - 9:45pm

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, todayannounced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit.

Key Points: 
  • WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, todayannounced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit.
  • Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m.
  • ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m.
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Aziyo Biologics Announces New Appointments to Board of Directors

Monday, September 21, 2020 - 9:05pm

Since December 2019, she has also served as a member of the board of directors of Mind Medicine (MindMed) Inc. a publicly-traded neuro-pharmaceutical company.

Key Points: 
  • Since December 2019, she has also served as a member of the board of directors of Mind Medicine (MindMed) Inc. a publicly-traded neuro-pharmaceutical company.
  • I couldnt be more excited to welcome Maybelle and Brigid, women of significant accomplishments, to our board of directors, said Ron Lloyd, President and Chief Executive Officer, Aziyo Biologics.
  • Their expertise across biologics and medical devices will complement the broad range of experience of our Board of Directors.
  • Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices.

Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device

Monday, September 21, 2020 - 3:03pm

The device uses a thin sheet of gold coated with virus-specific proteins that can bind with the SARS-CoV-2 virus.

Key Points: 
  • The device uses a thin sheet of gold coated with virus-specific proteins that can bind with the SARS-CoV-2 virus.
  • "Hoth is pleased to once again be working alongside some of the most renowned experts in the fields of engineering and public health research at GW," stated, Robb Knie, Chairman and CEO of Hoth Therapeutics.
  • A device that can provide immediate COVID-19 test results would have a dramatic impact on our economy returning to normal once again.
  • Hoth Therapeutics, Inc. isa clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders.

Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

Monday, September 21, 2020 - 2:00pm

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences , a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today that its co-founder and board member, Sir Marc Feldmann, will participate in the 2020 Tang Prize Masters Forum in Biopharmaceutical Science.

Key Points: 
  • SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences , a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today that its co-founder and board member, Sir Marc Feldmann, will participate in the 2020 Tang Prize Masters Forum in Biopharmaceutical Science.
  • Sir Marc Feldmann is one of the leaders of anti-TNF trials in the UK and US.
  • To see Sir Feldmanns presentation at the live-streamed 2020 Tang Prize awards program and Masters Forum, please visit the official Tang Prize website or follow its YouTube channel .
  • Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer.

Elektrofi and Takeda Pharmaceutical Company Enter into an Evaluation Agreement on Elektrofi’s Formulation Technology

Monday, September 21, 2020 - 1:30pm

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into an evaluation agreement with Takeda Pharmaceutical Company Limited (Takeda) for the potential use of the companys high concentration delivery technology.

Key Points: 
  • Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into an evaluation agreement with Takeda Pharmaceutical Company Limited (Takeda) for the potential use of the companys high concentration delivery technology.
  • Under the agreement, Takeda will evaluate Elektrofis microparticle-based formulation technology using a non-disclosed plasma protein for the purpose of engineering high-concentration, low-viscosity samples.
  • We are excited to initiate this exploratory program with Takeda, a leading pharmaceutical manufacturer, and to demonstrate the potential of our technology platform to generate small-volume delivery for protein therapeutics, said Chase Coffman, co-founder and CEO, Elektrofi.
  • By developing a breakthrough formulation platform technology, Elektrofi is addressing the long-standing and unmet need for stabilized, highly concentrated biologics through a proprietary microparticle technology.

PharmAbcine expands partnership with Samsung Biologics for PMC-403

Monday, September 21, 2020 - 1:00pm

DAEJEON, SouthKorea, Sept. 21, 2020 /PRNewswire/ --PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.

Key Points: 
  • DAEJEON, SouthKorea, Sept. 21, 2020 /PRNewswire/ --PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.
  • Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support.
  • PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibodies to treat cancer and neovascular disease.
  • PharmAbcine is developing PMC-403 as a therapeutic drug for both non ocular and ocular pathological vessel related diseases.

Zogenix Appoints Three Industry Leaders to Its Board of Directors

Monday, September 21, 2020 - 1:00pm

We are delighted to welcome Ms. Loewy, Ms. Stutts and Ms. Waynick to our Board of Directors, said Cam L. Garner, Chairman of the Board.

Key Points: 
  • We are delighted to welcome Ms. Loewy, Ms. Stutts and Ms. Waynick to our Board of Directors, said Cam L. Garner, Chairman of the Board.
  • Ms. Loewy has more than 25 years of experience in the biopharmaceutical industry and currently serves as a strategic business and financial advisor to life science companies.
  • Ms. Waynick has more than 25 years of experience as a legal and strategic advisor across multiple sectors, including the biopharmaceutical industry.
  • Through its subsidiary Modis Therapeutics, Zogenix is also developing MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

Monday, September 21, 2020 - 12:30pm

MacroGenics and Incyte have each established multiple development programs for retifanlimab, evaluating the anti-PD-1 molecule either as monotherapy or in combination with other agents.

Key Points: 
  • MacroGenics and Incyte have each established multiple development programs for retifanlimab, evaluating the anti-PD-1 molecule either as monotherapy or in combination with other agents.
  • Under the collaboration agreement with Incyte, MacroGenics is eligible to receive up to a total of $390 million in potential remaining development and regulatory milestones and up to $330 million in potential commercial milestones.
  • If retifanlimab is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 to 24 percent, on future worldwide net sales of the molecule.
  • MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.